This database contains 67 studies, archived under the term: "Case Control Study"
Click here to filter this large number of results.
Improvement of spontaneous speech in early stage Alzheimer’s with rivastigmine
Visch Brink, E. G.,
Van Rhee Temme, W.,
Rietveld, T.,
Krulder, J. W. M.,
Van Harskamp, F.,
Van der Cammen, T. J. M.
Objectives: Placebo-controlled trials have shown that rivastigmine can delay cognitive deterioration in patients with mild to moderate Alzheimer’s disease (AD). Benefits on cognitive functioning, as measured with the ADAS-Cog, occur on a daily dose of 6-12 mg when used for at least 6 months. The effect of rivastigmine on the adequacy of spontaneous speech is […]
The effects of glucose ingestion and glucose regulation on memory performance in older adults with mild cognitive impairment
Riby, L. M.,
Marriott, A.,
Bullock, R.,
Hancock, J.,
Smallwood, J.,
McLaughlin, J.
Background/objectives: Previous research investigating the impact of glucose ingestion and/or improvements in glucose regulation has found selective cognitive facilitation on episodic memory tasks in successful ageing and dementia. The present study aimed to extend this research to mild cognitive impairment (MCI).; Subjects/methods: In a repeated-measures design, 24 older adults with and 24 older adults without […]
CSF biomarker profile and diagnostic value in vascular dementia
Paraskevas, G. P.,
Kapaki, E.,
Papageorgiou, S. G.,
Kalfakis, N.,
Andreadou, E.,
Zalonis, I.,
Vassilopoulos, D.
Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 […]
Voxel-based morphometry in individual patients: a pilot study in early Huntington disease
Mühlau, M.,
Wohlschläger, A. M.,
Gaser, C.,
Valet, M.,
Weindl, A.,
Nunnemann, S.,
Peinemann, A.,
Etgen, T.,
Ilg, R.
Background and Purpose: Voxel-based morphometry (VBM) has proved a powerful method to detect subtle changes of gray matter (GM) at the group level but the role of VBM for the detection of GM changes in single subjects, especially in those with suspected neurodegenerative disorder, remains uncertain. Here, we performed single subject analyses in 22 patients […]
Efficacy and safety of memantine in Lewy body dementia
Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. An open, controlled, 16-week study was performed with […]
Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer’s disease
Kountouras, Jannis,
Boziki, Marina,
Gavalas, Emmanuel,
Zavos, Christos,
Grigoriadis, Nikolaos,
Deretzi, Georgia,
Tzilves, Dimitrios,
Katsinelos, Panagiotis,
Tsolaki, Magda,
Chatzopoulos, Dimitrios,
Venizelos, Ioannis
Infectious agents have been proposed as potential causes of Alzheimer’s disease (AD). Recently, we documented a high prevalence of Helicobacter pylori (Hp) infection in patients with AD. We aim to access the effect of Hp eradication on the AD cognitive (MMSE: Mini Mental State Examination and CAMCOG: Cambridge Cognitive Examination for the Elderly) and functional […]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease
Beglinger, Leigh J.,
Adams, Williams H.,
Paulson, Henry,
Fiedorowicz, Jess G.,
Langbehn, Douglas R.,
Duff, Kevin,
Leserman, Anne,
Paulsen, Jane S.
Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders
Vellas, Bruno,
Black, R.,
Thal, Leon J.,
Fox, Nick C.,
Daniels, M.,
McLennan, G.,
Tompkins, C.,
Leibman, C.,
Pomfret, M.,
Grundman, Michael
Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery […]